Press release
Verastem Oncology Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress
Announced Clinical Collaboration with Amgen to Evaluate VS-6766 with LUMAKRAS™ in Non-Small Cell Lung Cancer in Upcoming Clinical Trial Updated Data from
About this update from Verastem, Inc.
[{"type":"text","content":"\nAnnounced Clinical Collaboration with Amgen to Evaluate VS-6766 with LUMAKRAS™ in Non-Small Cell Lung Cancer in Upcoming Clinical Trial\n\nUpdated Data from Investigator-Sponsored Phase 1/2 FRAME Study of VS-6766 and Defactinib in Low-Grade Serous Ovarian Cancer Presented at ESMO 2021\n\nAppointed Louis J. Denis, M.D., as Chief Medical Officer\n\n BOSTON--(BUSINESS WIRE)--\nVerastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended September 30, 2021 and highlighted recent progress.\n\n“The third quarter was marked by several significant milestones for Verastem as we continued to advance our development program to establish VS-6766 as a backbone therapy across RAS pathway-driven solid tumors, including our entry into a clinical collaboration with Amgen to evaluate VS-6766 in combination with LUMAKRAS™ (sotorasib) in patients with KRAS G12C-mutant NSCLC. This Phase 1/2 study will investigate the potential of a more complete vertical blockade along the RAS pathway,” said Brian Stuglik, Chief Executive Officer of Verastem Oncology. “We were also pleased to highlight updated data from the investigator-initiated Phase 1/2 FRAME study that were presented at ESMO 2021 and continue to demonstrate encouraging response rates, along with 23.0 months PFS, in patients with low-grade serous ovarian cancer (LGSOC), including in patients who had previously received a MEK inhibitor.”\n\nRecent Corporate Highlights\n\nLow-Grade Serous Ovarian Cancer (LGSOC)\n\n\nUpdated data from the LGSOC cohort of the ongoing, investigator-sponsored Phase 1/2 FRAME study evaluating VS-6766 in combination with defactinib in patients with LGSOC were presented at the European Society of Medical Oncology (ESMO) Congress 2021. Results show encouraging response rates and progression-free survival (PFS). The initial results of the FRAME study were the basis for the U.S. Food and Drug Administration granting Breakthrough Therapy designation for the combination in LGSOC.\n\n\nMedian PFS across all patients was 23.0 months (n=24)\n\n\nOverall response rate (ORR) across all patients was 46% (11 of 24 patients)\n\n\nORR across patients with KRAS mutant LGSOC was 64% (7 of 11 patients)\n\n\nORR across patients with KRAS wild type LGSOC was 44% (4 o...